Notwithstanding positive clinical data, copyright's Vyndamax, a therapy for hereditary transthyretin-mediated amyloidosis (hATTR), is experiencing significant resistance from managed care entities. Such insurers are https://jessetppt115868.blogripley.com/42841118/company-s-medication-faces-is-meeting-pbm-challenges-the-look-at-reimbursement-fights